Human Genome Sciences, Inc

Published Date: 04/11/2011
Category: Emerging Technologies & Scientific Research

Research Report Decription

Human Genome Sciences, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.Features:

• Detailed information on Human Genome Sciences, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Human Genome Sciences, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Human Genome Sciences, Inc. including a breakdown and examination of key business segments
• Intelligence on Human Genome Sciences, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Human Genome Sciences, Inc., such as business expansion, restructuring, and contract winsLarge number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

Reasons to Purchase: Gain understanding of  Human Genome Sciences, Inc. and the factors that influence its strategies Track strategic initiatives of the company and latest corporate news and actions Assess Human Genome Sciences, Inc. as a prospective partner, vendor or supplier Support sales activities by understanding your customers' businesses better Stay up to date on Human Genome Sciences, Inc.’s business structure, strategy and prospectss

Companies Mentioned:

HGS

Paper Highlights:

Human Genome Sciences (HGS), a commercial-stage biopharmaceutical company, is engaged in the discovery and development of human protein and antibody drugs. The company’s drug Benlysta received FDA approval for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy. It primarily operates in the US. The company is headquartered in Rockville, Maryland and employed about 1,100 people as of February 01, 2011.  The company recorded revenues of $157.4 million during the financial year (FY) ended December 2010, a decrease of 42.9% over FY2009. The operating loss of the company was $190.8 million during FY2010, as compared with an operating profit of $6.2 million in FY2009. The net loss was $233.2 million in FY2010, as compared with a net profit of $5.7 million in FY2009.